UndisclosedSPACHealthcare & Life Sciences
TriGemX Bio and SPAC TCGX file draft S-4
TriGemX Bio, developing elismetrep as a potential first-in-class migraine treatment, and Nasdaq-listed SPAC TCGX Acquisition Corp. confidentially submitted a draft Form S-4 registration statement to the SEC for their proposed business combination.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Get healthcare deals like this every morning
The day's biggest deals in five minutes. Free, with no paywalled links.